[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-332172-en":59,"doc-seo-332172-105":81},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":4},332172,4398048950312,"Violet","https://ap-avatar.wpscdn.com/avatar/400002538284de19e3c?_k=1778320343897328908","Advances in MET tyrosine kinase inhibitors in gastric cancer","Gastric cancer is among the most frequently occurring cancers and a leading cause of cancer-related deaths globally. Its heterogeneity and distinct molecular subtypes require biomarker-guided, molecular-based treatment strategies. MET is a receptor tyrosine kinase involved in key physiologic processes, while aberrant MET pathway activation drives tumor proliferation and metastasis. This review summarizes current progress of MET tyrosine kinase inhibitors, including savolitinib, tepotinib, capmatinib, and crizotinib, and discusses testing challenges, resistance mechanisms, and future directions.","Cancer Biol Med 2024. doi: 10.20892/j.issn.2095-3941.2024.0044  \nREVIEW  \nAdvances in MET tyrosine kinase inhibitors in gastric cancer  \nYifan Zhang1, Lin Shen2, Zhi Peng2  \n1 Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China; 2State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China  \n\n| ABSTRACT | Gastric cancer is among the most frequently occurring cancers and a leading cause of cancer-related deaths globally. Because gastric cancer is highly heterogenous and comprised of different subtypes with distinct molecular and clinical characteristics, the management of gastric cancer calls for better-defined, biomarker-guided, molecular-based treatment strategies. MET is a receptor tyrosine kinase mediating important physiologic processes, such as embryogenesis, tissue regeneration, and wound healing. However, mounting evidence suggests that aberrant MET pathway activation contributes to tumour proliferation and metastasis in multiple cancer types, including gastric cancer, and is associated with poor patient outcomes. As such, MET-targeting therapies are being |\n| --- | --- |\n| KEYWORDS | actively developed and promising progress has been demonstrated, especially with MET tyrosine kinase inhibitors. This review aims to briefly introduce the role of MET alterations in gastric cancer and summarize in detail the current progress of MET tyrosine kinase inhibitors in this disease area with a focus on savolitinib, tepotinib, capmatinib, and crizotinib. Building on current knowledge, this review further discusses existing challenges in MET alterations testing, possible resistance mechanisms to MET inhibitors, and future directions of MET-targeting therapies.\u003Cbr>Gastric cancer; MET alterations; MET tyrosine kinase inhibitors; savolitinib; MET testing |\n\nIntroduction  \nGastric cancer is one of the most common cancers worldwide and a leading cause of cancer-related deaths1,2 . In 2020 alone there were > 1 million new cases of gastric cancer and an estimated 769,000 gastric cancer-related deaths globally, ranking fifth for incidence and fourth for mortality among all cancer types1. Gastric cancer has a poor overall 5-year survival rate of 32.4%, likely because > 60% of gastric cancer cases are only detected at an advanced stage, which is associated with poorer survival compared to localised disease3. Gastric cancer is highly heterogenous, comprised of different subtypes with distinct molecular and clinical characteristics, and calls for better-defined, biomarker-guided, molecular-based treatment  \nCorrespondence to: Zhi Peng  \nE-mail: [zhipeng@bjmu.edu.cn](zhipeng@bjmu.edu.cn)  \nORCID ID: [https://orcid.org/0000-0003-4063-9813](https://orcid.org/0000-0003-4063-9813)  \nReceived January 22, 2024; accepted April 11, 2024;  \npublished online May 10, 2024. Available [at www.cancerbiomed.org](at www.cancerbiomed.org)  \n©2024 The Authors. Creative Commons Attribution-NonCommercial 4.0 International License  \nstrategies4. In addition to human epidermal growth factor receptor 2 (HER2), Claudin 18.2, and programmed deathligand 1 (PD-L1), MET, a type of receptor tyrosine kinase (RTK), has also emerged as a prominent biomarker candidate and therapeutic target for gastric cancer in recent years4.  \nThe MET oncogene was initially isolated in 1984 from a humanosteosarcoma-derived cell line5. The MET ligand was shown tobe hepatocyte growth factor (HGF) in 19916. HGF/MET signalling mediates important physiologic processes, such as embryogenesis7, muscle development8,9, and tissue regeneration10. However, MET also has multifaceted roles in tumor biology through oncogene addiction, expedience, and inherence,11 and","cbCaihwSLwirVAUw","https://ap.wps.com/l/cbCaihwSLwirVAUw","pdf",620678,15,"English","en",105,"# Introduction\n## MET alterations in gastric cancer\n## Current progress of MET tyrosine kinase inhibitors\n## Challenges in MET testing and resistance mechanisms\n## Future directions","[{\"question\":\"Why are biomarker-guided strategies important for gastric cancer management?\",\"answer\":\"Gastric cancer is highly heterogeneous and consists of subtypes with distinct molecular and clinical characteristics, so molecular-based, biomarker-guided treatment is needed.\"},{\"question\":\"What role does MET play in gastric cancer?\",\"answer\":\"MET is a receptor tyrosine kinase whose aberrant pathway activation contributes to tumor proliferation and metastasis, correlating with poor patient outcomes.\"},{\"question\":\"Which MET tyrosine kinase inhibitors are highlighted in the review?\",\"answer\":\"The review focuses on savolitinib, tepotinib, capmatinib, and crizotinib.\"}]","Advances in MET tyrosine kinase inhibitors in gastric cancer | PDF",1789997183,38,{"code":4,"msg":82,"data":83},"ok",{"site_id":75,"language":74,"slug":84,"title":65,"keywords":85,"description":66,"schema_data":86,"social_meta":140,"head_meta":142,"extra_data":144,"updated_unix":145},"advances-in-met-tyrosine-kinase-inhibitors-in-gastric-cancer","",{"@graph":87,"@context":139},[88,102,122],{"@type":89,"itemListElement":90},"BreadcrumbList",[91,95,97,100],{"item":92,"name":93,"@type":94,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":96,"name":9,"@type":94,"position":14},"https://docshare.wps.com/document/",{"item":98,"name":40,"@type":94,"position":99},"https://docshare.wps.com/document/research-report/",3,{"item":101,"name":65,"@type":94,"position":19},"https://docshare.wps.com/document/advances-in-met-tyrosine-kinase-inhibitors-in-gastric-cancer/332172/",{"url":101,"name":65,"@type":103,"image":104,"author":109,"headline":65,"publisher":111,"fileFormat":114,"inLanguage":74,"description":66,"dateModified":115,"datePublished":116,"encodingFormat":114,"isAccessibleForFree":117,"interactionStatistic":118},"DigitalDocument",{"url":105,"@type":106,"width":107,"height":108},"https://docshare.wps.com/thumbnails/advances-in-met-tyrosine-kinase-inhibitors-in-gastric-cancer/332172.png","ImageObject",300,407,{"name":63,"@type":110},"Person",{"url":92,"name":112,"@type":113},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":119,"interactionType":120,"userInteractionCount":29},"InteractionCounter",{"@type":121},"ViewAction",{"@type":123,"mainEntity":124},"FAQPage",[125,131,135],{"name":126,"@type":127,"acceptedAnswer":128},"Why are biomarker-guided strategies important for gastric cancer management?","Question",{"text":129,"@type":130},"Gastric cancer is highly heterogeneous and consists of subtypes with distinct molecular and clinical characteristics, so molecular-based, biomarker-guided treatment is needed.","Answer",{"name":132,"@type":127,"acceptedAnswer":133},"What role does MET play in gastric cancer?",{"text":134,"@type":130},"MET is a receptor tyrosine kinase whose aberrant pathway activation contributes to tumor proliferation and metastasis, correlating with poor patient outcomes.",{"name":136,"@type":127,"acceptedAnswer":137},"Which MET tyrosine kinase inhibitors are highlighted in the review?",{"text":138,"@type":130},"The review focuses on savolitinib, tepotinib, capmatinib, and crizotinib.","https://schema.org",{"og:url":101,"og:type":141,"og:title":65,"og:site_name":112,"og:description":66},"article",{"robots":143,"canonical":101},"index,follow",{"doc_id":61,"site_id":75},1790198753]